

October 06, 2016

To,  
Dy. General Manager  
Department of Corporate Services.  
Bombay Stock Exchange Ltd.  
P. J. Towers, Dalal Street,  
Fort, Mumbai- 400 001.

Dear Sir,

**Sub: Statement of Investor Complaints.**

**Ref: Script Code: 532296**

Pursuant to Regulation 13 (3) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find below the statement of Investor complaints for the quarter ended September 30, 2016:

SNo	Particulars	Details
1	No. of Investor Complaints pending at the beginning of the quarter	0
2	No. of Investor Complaints received during the quarter	50
3	No. of Investor Complaints disposed of during the quarter	50
4	No. of Investor Complaints those remaining unresolved at the end of the quarter	0

Please take the same on records.

Yours Faithfully,  
For Glenmark Pharmaceuticals Ltd.



**Sanjay Kumar Chowdhary**  
Company Secretary & Compliance Officer

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)